Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 2
2011 4
2012 6
2013 5
2014 5
2015 6
2016 1
2017 3
2018 3
2019 2
2020 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders.
Kuiper JJ, Prinz JC, Stratikos E, Kuśnierczyk P, Arakawa A, Springer S, Mintoff D, Padjen I, Shumnalieva R, Vural S, Kötter I, van de Sande MG, Boyvat A, de Boer JH, Bertsias G, de Vries N, Krieckaert CL, Leal I, Vidovič Valentinčič N, Tugal-Tutkun I, El Khaldi Ahanach H, Costantino F, Glatigny S, Mrazovac Zimak D, Lötscher F, Kerstens FG, Bakula M, Viera Sousa E, Böhm P, Bosman K, Kenna TJ, Powis SJ, Breban M, Gul A, Bowes J, Lories RJ, Nowatzky J, Wolbink GJ, McGonagle DG, Turkstra F; EULAR studygroup MHC-I-opathies. Kuiper JJ, et al. Among authors: krieckaert cl. Ann Rheum Dis. 2023 Jul;82(7):887-896. doi: 10.1136/ard-2022-222852. Epub 2023 Mar 27. Ann Rheum Dis. 2023. PMID: 36987655 Free PMC article. Review.
EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases.
Krieckaert CL, van Tubergen A, Gehin JE, Hernández-Breijo B, Le Mélédo G, Balsa A, Böhm P, Cucnik S, Elkayam O, Goll GL, Hooijberg F, Jani M, Kiely PD, McCarthy N, Mulleman D, Navarro-Compán V, Payne K, Perry ME, Plasencia-Rodriguez C, Stones SR, Syversen SW, de Vries A, Ward KM, Wolbink G, Isaacs JD. Krieckaert CL, et al. Ann Rheum Dis. 2023 Jan;82(1):65-73. doi: 10.1136/annrheumdis-2022-222155. Epub 2022 May 12. Ann Rheum Dis. 2023. PMID: 35551063
[TNF inhibitors: the role of drug levels].
Krieckaert CL, Vogelzang EH, Rispens T, Wolbink G. Krieckaert CL, et al. Ned Tijdschr Geneeskd. 2014;158:A6707. Ned Tijdschr Geneeskd. 2014. PMID: 24754928 Review. Dutch.
Biologicals and bone loss.
Krieckaert CL, Lems WF. Krieckaert CL, et al. Ther Adv Musculoskelet Dis. 2012 Aug;4(4):245-7. doi: 10.1177/1759720X12441275. Ther Adv Musculoskelet Dis. 2012. PMID: 22859923 Free PMC article.
The effect of certolizumab drug concentration and anti-drug antibodies on TNF neutralisation.
Berkhout LC, Vogelzang EH, Hart MM, Loeff FC, Dijk L, Derksen NIL, Wieringa R, van Leeuwen WA, Krieckaert CLM, de Vries A, Nurmohamed MT, Wolbink GJ, Rispens T. Berkhout LC, et al. Among authors: krieckaert clm. Clin Exp Rheumatol. 2020 Mar-Apr;38(2):306-313. doi: 10.55563/clinexprheumatol/nlr4r8. Epub 2019 Aug 30. Clin Exp Rheumatol. 2020. PMID: 31498069 Free article.
31 results